August 22nd 2017
Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses unique characteristics of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).
August 11th 2017
Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, sheds light on the FDA approval of CPX-351 (Vyxeos) in acute myeloid leukemia (AML).
April 2nd 2014
Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses the excitement around FLT3 inhibitors for the treatment of acute myeloid leukemia (AML).
February 25th 2014
Harry Erba, MD, PhD, discusses the frequency in which patients with chronic-phase chronic myeloid leukemia (CML) fail to achieve a BCR-ABL transcript level below 10% after 3 months of treatment with imatinib.
May 22nd 2013
Harry Erba, MD, PhD, Professor of Medicine, Director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses treating a patient with acute myeloid leukemia with curative intent.
April 9th 2013
Harry Erba, MD, PhD, Professor of Medicine, Director, Hematologic Malignancy Program, University of Alabama at Birmingham, comments on the diagnosis and testing of a patient with chronic myeloid leukemia (CML).
March 18th 2013
Harry Erba, MD, PhD, from the University of Alabama at Birmingham, discusses the use of second-generation tyrosine kinase inhibitors for the treatment of chronic phase chronic myeloid leukemia.
January 23rd 2013
Harry Erba, MD, PhD, discusses the results of a phase II study analyzing azacitidine and gemtuzumab ozogamicin as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 AML.
December 9th 2012
Harry Erba, MD, PhD, professor of medicine and director, University of Alabama at Birmingham Hematologic Malignancy Program, explains the declining treatment-related mortality (TRM) rates in AML patients.
May 8th 2012
Dr. Harry Erba, from University of Michigan Health System, Discusses Molecular Monitoring for CML
March 28th 2012
Dr. Harry Erba, from the University of Michigan Health System, Discusses the Frontline Treatment of CML
February 27th 2012
Dr. Harry Erba, from the University of Michigan Health System, Describes Proper Diagnostic Testing of CML